Condition
Extranodal NK/T-cell Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Extranodal NK/T-cell Lymphoma clinical trials that are recruiting, in China. By phase: Phase 2 (1), Phase 3 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest Extranodal NK/T-cell Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Epstein-Barr virus–positive T/NK-cell lymphoproliferative diseases in large patient groups | — | Shanghai, Shanghai Municipality | Recruiting | Jul 27, 2026 |
| Frontline immunotherapy versus chemotherapy induction for advanced Extranodal NK/T-cell lymphoma, followed by autologous stem cell transplant | Phase 3 | Shanghai, Shanghai Municipality | Recruiting | Jul 1, 2026 |
| Tislelizumab plus Zeprumetostat in relapsed or refractory NK/T-cell lymphoma | Phase 1/2 | Shanghai, Shanghai Municipality | Recruiting | Mar 31, 2026 |
| Treatment for untreated extranodal NK/T-cell lymphoma using a combination of drugs | Phase 2 | Beijing, Beijing Municipality | Recruiting | Feb 13, 2025 |
All recruiting trials (4)
-
Epstein-Barr virus–positive T/NK-cell lymphoproliferative diseases in large patient groups
This study follows patients with EBV-positive T/NK-cell disorders to see how they present, what treatments are used, and how they respond over time.
-
Frontline immunotherapy versus chemotherapy induction for advanced Extranodal NK/T-cell lymphoma, followed by autologous stem cell transplant
This study tests whether starting with immunotherapy plus targeted drugs is more effective than standard chemotherapy to help patients with advanced extranodal NK/T‑cell lymphoma, then all patients who reach a strict remission proceed to autologous stem cell transplantation.
-
Tislelizumab plus Zeprumetostat in relapsed or refractory NK/T-cell lymphoma
This study tests whether combining tislelizumab with zeprumetostat can help patients with relapsed or refractory NK/T-cell lymphoma after prior chemotherapy.
-
Treatment for untreated extranodal NK/T-cell lymphoma using a combination of drugs
This study is testing a new combination of drugs to see if it can help people with untreated extranodal NK/T-cell lymphoma feel better and improve their chances of survival.
Related topics
Quick answers
How many Extranodal NK/T-cell Lymphoma clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.